Investor Relations
CelsyncTM, New Immune System-Enhancing Nutrient, Now Available.
New Glyconutrient discovery is based on Nobel-prize
winning research.
Philadelphia, PA May 13, 2005 – Glycology, Inc (Pink Sheets:GYLG)
introduced Celsync™ today, a breakthrough all-natural product
that enhances the immune system by improving the way cells communicate.
Available at www.celsync.com,
CelsyncTM is an all-natural glyconutrient that surrounds and coats
each cell with all eight essential saccharides, a form of carbohydrate.
Glyconutrients are so important to our immune systems, Nobel Prize
winning research suggests, that maintaining healthy levels may help
prevent a wide range of illnesses. The eight essential saccharides
are instrumental in directing antibodies to the site of infections.
Without proper communication between cells (signals carried by glyconutrients
like those in CelsyncTM) necessary antibodies and nutrients can
be blocked from even reaching cells. Celsync’s role is to
boost the body’s immune system, and prevent cellular transfer
abnormalities, thus defending against disease. It may even heal
and improve existing conditions.
About Glycology.
Glycology, Inc. is a life sciences company committed
to developing new beneficial technology that enhances and improves
human health and performance. The company's flagship product, CelsyncTM,
is an all natural dietary supplement based on Nobel Prize winning
molecular science.
Corporately, Glycology, Inc. currently has 2,800,000
shares outstanding, with a float of 360,000 shares.
For more information about Glycology, Inc go to
http://www.glycology.com
or Celsync™, go to http://www.celsync.com
Safe Harbor statement under the Private Securities
Litigation Reform Act of 1995: Statements in this news release looking
forward in time involve risks and uncertainties, including the risks
associated with the effect of changing economic conditions, trends
in the products markets, variations in the company's cash flow,
market acceptance risks, technical development risks, seasonality
and other risk factors
Contact:
Mark T. Dunbar
Investor Relations.
1-800-609-6517 ext 701
|
Home
